Your browser is no longer supported. Please, upgrade your browser.
GTHX G1 Therapeutics, Inc. monthly Stock Chart
GTHX [NASD]
G1 Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.55 Insider Own0.20% Shs Outstand33.46M Perf Week-8.75%
Market Cap2.01B Forward P/E- EPS next Y-3.09 Insider Trans- Shs Float25.37M Perf Month11.82%
Income-73.90M PEG- EPS next Q-0.68 Inst Own82.90% Short Float10.20% Perf Quarter22.17%
Sales- P/S- EPS this Y-181.70% Inst Trans12.97% Short Ratio10.11 Perf Half Y43.68%
Book/sh5.38 P/B11.15 EPS next Y-11.00% ROA-48.30% Target Price62.67 Perf Year142.91%
Cash/sh5.62 P/C10.67 EPS next 5Y- ROE-52.60% 52W Range18.03 - 69.57 Perf YTD202.42%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-13.76% Beta-
Dividend %- Quick Ratio13.60 Sales past 5Y- Gross Margin- 52W Low232.69% ATR3.39
Employees44 Current Ratio13.60 Sales Q/Q- Oper. Margin- RSI (14)49.55 Volatility5.97% 4.88%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.70% Profit Margin- Rel Volume12.77 Prev Close62.94
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume256.01K Price60.00
Recom1.80 SMA20-2.47% SMA509.04% SMA20055.02% Volume3,268,804 Change-4.67%
Sep-10-18Resumed BTIG Research Buy $80
May-29-18Initiated H.C. Wainwright Buy $61
May-18-18Reiterated Needham Buy $42 → $60
Sep-19-18 09:41AM  G1 Therapeutics' stock drops on heavy volume after stock offering MarketWatch
08:47AM  The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering Benzinga
Sep-18-18 09:37PM  G1 Therapeutics Announces Pricing of Offering of Common Stock GlobeNewswire -5.21%
Sep-17-18 04:01PM  G1 Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
06:00AM  G1 Therapeutics to Report Myelopreservation Data from Randomized Phase 2 Trial of Trilaciclib/Chemotherapy/Tecentriq® in Small Cell Lung Cancer in Fourth Quarter 2018 GlobeNewswire
Sep-13-18 07:00AM  G1 Therapeutics Announces Appointment of Garry Nicholson to Board of Directors GlobeNewswire
Sep-04-18 02:38PM  Inside The List: Highest-Paid Public Company CEOs American City Business Journals
Aug-28-18 06:00AM  G1 Therapeutics to Present at H.C. Wainwright Investment Conference on September 5, 2018 GlobeNewswire
Aug-09-18 05:10PM  G1 Therapeutics stock rises following earnings report American City Business Journals +8.97%
Aug-08-18 04:01PM  G1 Therapeutics Provides Second Quarter 2018 Corporate and Financial Update GlobeNewswire
02:30PM  G1 Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-18 06:00AM  G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 14, 2018 GlobeNewswire
Aug-01-18 06:00AM  G1 Therapeutics to Provide Second Quarter 2018 Corporate and Financial Update on August 8, 2018 GlobeNewswire +5.20%
Jul-09-18 05:25PM  The Triangle's top inside stock sales in the first half of 2018 American City Business Journals
07:00AM  G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel GlobeNewswire
Jun-25-18 08:08AM  G1 Therapeutics registers to sell $125 million worth of shares when needed in future American City Business Journals
Jun-08-18 07:00AM  G1 Therapeutics Announces Appointment of New Members to the Board of Directors GlobeNewswire
Jun-06-18 08:20AM  Analysis: Positioning to Benefit within China Biologic Products, Merus N.V, Adient, G1 Therapeutics, Westport Fuel, and AppFolio Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-04-18 05:34PM  Hatteras Venture Partners sells 20 percent of shares in G1 American City Business Journals -10.16%
Jun-02-18 09:00AM  G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-30-18 03:18PM  Glancy Prongay & Murray LLP Continues Investigation on Behalf of G1 Therapeutics, Inc. Investors (GTHX) Business Wire -6.65%
07:00AM  Wired News - Protalix BioTherapeutics Presents Data About Fabry Disease Patients Screened in Phase-III BALANCE Study ACCESSWIRE
May-29-18 10:06PM  Glancy Prongay & Murray LLP Begins Investigation on Behalf of G1 Therapeutics, Inc. Investors (GTHX) Business Wire
03:44PM  HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets Benzinga
May-16-18 05:07PM  G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-09-18 03:46PM  Edited Transcript of GTHX.O earnings conference call or presentation 3-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-03-18 04:01PM  G1 Therapeutics Provides First Quarter 2018 Corporate and Financial Update GlobeNewswire
May-01-18 07:00AM  G1 Therapeutics to Present at UBS Global Healthcare Conference in May 2018 GlobeNewswire
Apr-26-18 07:00AM  G1 Therapeutics to Provide First Quarter 2018 Corporate and Financial Update on May 3, 2018 GlobeNewswire
Apr-16-18 06:00AM  G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer GlobeNewswire
Apr-09-18 07:40AM  Research Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis, and G1 THERAPEUTICS with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
07:00AM  G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitors Trilaciclib and G1T38 at the 2018 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-29-18 08:48AM  These 3 Biotech Stocks Are Soaring, but Are They Buys Now? Motley Fool
Mar-16-18 08:10AM  New Research Coverage Highlights Amarin, Corbus Pharmaceuticals, Green Brick Partners, Immutep, Texas Capital Bancshares, and G1 THERAPEUTICS Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-14-18 02:25PM  G1 CEO talks 2018 growth American City Business Journals
08:48AM  G1 Therapeutics (GTHX) in Focus: Stock Moves 8.9% Higher Zacks
Mar-12-18 04:05PM  G1 Therapeutics Announces Closing of Offering of Common Stock GlobeNewswire
Mar-07-18 09:54PM  G1 Therapeutics Announces Pricing of Offering of Common Stock GlobeNewswire +14.35%
Mar-05-18 04:18PM  G1 Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
03:30PM  G1 sees stock bump on big data readout American City Business Journals
07:40AM  Wired News FDA Granted Fast Track Designation to FibroGens Pamrevlumab for Locally Advanced Unresectable Pancreatic Cancer ACCESSWIRE
06:00AM  G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Benefits in Patients with Small Cell Lung Cancer GlobeNewswire
Mar-01-18 07:00AM  G1 Therapeutics to Present at Investor Conferences in March 2018 GlobeNewswire +5.67%
Feb-26-18 06:19PM  Edited Transcript of GTHX.O earnings conference call or presentation 21-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Feb-21-18 04:01PM  G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights GlobeNewswire
Feb-14-18 07:00AM  G1 Therapeutics to Report Fourth Quarter and Full-Year 2017 Financial Results on February 21, 2018 GlobeNewswire
Jan-02-18 07:00AM  G1 Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-18-17 07:00AM  G1 Therapeutics Added to Nasdaq Biotechnology Index GlobeNewswire
Dec-06-17 04:54PM  G1 Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-28-17 07:00AM  G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer GlobeNewswire
Nov-11-17 12:01AM  [$$] Triggering a Debt Bomb Barrons.com
Nov-08-17 07:30AM  G1 Therapeutics Reports Third Quarter 2017 Financial Results and Recent Operational Highlights GlobeNewswire
07:00AM  G1 Therapeutics Makes Key Executive Appointments GlobeNewswire
Nov-07-17 08:00AM  G1 Therapeutics to Present at Stifel 2017 Healthcare Conference GlobeNewswire
Nov-06-17 07:00AM  G1 Therapeutics Announces Publication in Cancer Discovery Demonstrating That CDK4/6 Inhibition Enhances the Anti-Tumor T Cell Response GlobeNewswire
Jun-09-17 10:42AM  Retail Investors: Your IPOs Are Here Benzinga
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.